跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

SML1107

Sigma-Aldrich

SGC0946

≥98% (HPLC)

别名:

1-(3-((((2R,3S,4R,5R)-5-(4-Amino-5-bromo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)(isopropyl)amino)propyl)-3-(4-(tert-butyl)phenyl)urea, 5-Bromo-7-[5-deoxy-5-[[3-[[[[4-(1,1-dimethylethyl)phenyl]amino]carbonyl]amino]propyl](1-methylethyl)amino]-beta-D-7H-Pyrrolo[2,3-d]pyrimidin-4-amine

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C28H40BrN7O4
CAS号:
1561178-17-3
分子量:
618.57
MDL编号:
MFCD26523136
UNSPSC代码:
12352200
PubChem化学物质编号:
329825482
NACRES:
NA.77

质量水平

100

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 20 mg/mL, clear

储存温度

−20°C

SMILES字符串

BrC1=CN([C@@H]2O[C@H](CN(CCCNC(NC3=CC=C(C(C)(C)C)C=C3)=O)C(C)C)[C@@H](O)[C@H]2O)C4=C1C(N)=NC=N4

InChI

1S/C28H40BrN7O4/c1-16(2)35(12-6-11-31-27(39)34-18-9-7-17(8-10-18)28(3,4)5)14-20-22(37)23(38)26(40-20)36-13-19(29)21-24(30)32-15-33-25(21)36/h7-10,13,15-16,20,22-23,26,37-38H,6,11-12,14H2,1-5H3,(H2,30,32,33)(H2,31,34,39)/t20-,22-,23-,26-/m1/s1

InChI key

IQCKJUKAQJINMK-HUBRGWSESA-N

相关类别

生化/生理作用

SGC0946 is a potent and selective inhibitor of Histone H3-lysine79 (H3K79) methyltransferase DOT1L with an IC50 of 0.3 nM in a radioactive enzyme assay, and over 100-fold selectivity for DOT1L over other histone methyltransferases. In cell studies, SGC0946 reduces H3K79 dimethylation with an IC50 of 2.6 nM in A431 cells and 8.8 nM in MCF10A cells. SGC0946 was found to selectively kills cells transformed with the MLL-AF9 fusion oncogene in an in vitro model of leukemia. For full characterization details, please visit the SGC0946 probe summary on the Structural Genomics Consortium (SGC) website.

SGC0649 is the negative control for the active probe, SGC0946. To request a sample of the negative control from the SGC, click here.

To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc
SGC0946 is a potent and selective inhibitor of Histone H3-lysine79 (H3K79) methyltransferase DOT1L.

特点和优势

SGC0946 is an epigenetic chemical probe available through a partnership with the Structural Genomics Consortium (SGC). To learn more and view other SGC epigenetic probes, visit sigma.com/SGC.
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

其他说明

SGC0946 has been expertly reviewed and recommended by the Chemical Probes Portal. For more information, please visit the SGC0946 probe summary on the Chemical Probes Portal website.

相关产品

产品编号
说明
价格

U4885

UNC0638 水合物, ≥98% (HPLC)

SML0067

IOX1, ≥97% (HPLC)

SML0352

PFI-1, ≥98% (HPLC)

SML0652

IOX2, ≥98% (HPLC)

SML0662

UNC1215, ≥98% (HPLC)

SML0701

GSK-J4, ≥98% (HPLC)

SML0709

GSK-J1, ≥98% (HPLC)

SML0768

GSK2801, ≥98% (HPLC)

SML0766

GSK343, ≥98% (HPLC)

SML0778

UNC1999, ≥98% (HPLC)

SML0974

(+/-)-JQ1, ≥98% (HPLC)

SML0992

Bromosporine, ≥98% (HPLC)

SML0939

PFI-3, ≥98% (HPLC)

SML1037

UNC0642, ≥98% (HPLC)

SML1072

GSK-LSD1, ≥98% (HPLC)

SML1133

SGC-CBP30, ≥98% (HPLC)

SML1134

I-CBP112, ≥98% (HPLC)

SML1184

OF-1, ≥98% (HPLC)

SML1209

OICR-9429, ≥98% (HPLC)

SML1242

SGC707, ≥98% (HPLC)

SML1279

LLY-507, ≥97% (HPLC)

SML1276

BAZ2-ICR, ≥98% (HPLC)

PZ0307

PFI-4, ≥98% (HPLC)

SML1408

(R)-PFI-2, ≥97% (HPLC)

SML1410

A-366, ≥98% (HPLC)

SML1486

NI-57, ≥98% (HPLC)

PZ0312

（S）-PFI-2

SML1534

I-BRD9, ≥98% (HPLC)

象形图

Skull and crossbones
GHS06

警示用语：

Danger

危险声明

H301

危险分类

Acute Tox. 3 Oral

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000414880
0000414880
0000251480
0000251478
0000241538

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Hao Zhang et al.
eLife, 9 (2020-10-02)
Aberrant HOXA9 expression is a hallmark of most aggressive acute leukemias, notably those with KMT2A (MLL) gene rearrangements. HOXA9 overexpression not only predicts poor diagnosis and outcome but also plays a critical role in leukemia transformation and maintenance. However, our
Julia Gobl et al.
Vaccines, 8(2) (2020-04-05)
Epigenetic mechanisms have not been characterized in ticks despite their importance as vectors of human and animal diseases worldwide. Our investigation identifies and functionally characterizes the orthologue of S-adenosylmethionine (SAM) binding methyltransferase enzyme, disruptor of telomeric silencing 1-like (DOT1L) in
Giovanni Nassa et al.
Science advances, 5(2), eaav5590-eaav5590 (2019-02-19)
Breast cancer (BC) resistance to endocrine therapy results from constitutively active or aberrant estrogen receptor α (ERα) signaling, and ways to block ERα pathway in these tumors are sought after. We identified the H3K79 methyltransferase DOT1L as a novel cofactor
Christiaan J Stavast et al.
Leukemia (2021-11-07)
MIR139 is a tumor suppressor and is commonly silenced in acute myeloid leukemia (AML). However, the tumor-suppressing activities of miR-139 and molecular mechanisms of MIR139-silencing remain largely unknown. Here, we studied the poorly prognostic MLL-AF9 fusion protein-expressing AML. We show
Kazuya Ishiguro et al.
Haematologica, 104(1), 155-165 (2018-09-02)
Epigenetic alterations play an important role in the pathogenesis in multiple myeloma, but their biological and clinical relevance is not fully understood. Here, we show that DOT1L, which catalyzes methylation of histone H3 lysine 79, is required for myeloma cell
查看所有相关文献

商品

Discover Bioactive Small Molecules for Gene Regulation

We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门